[A SHV-derived extended-spectrum beta-lactamase (SHV-12) produced by an Escherichia coli recovered from wound abscess in post operative case with rectal carcinoma].
A 62-year-old woman admitted for rectal carcinoma suffered from a post-operative bacterial infection. Oxy-imino-beta-lactams including cefotiam (CTM) and cefozopran (CZOP) were prescribed for this case, but the patient developed a wound abscess followed by peritonitis. She recovered from the bacterial infection after drainage and recurrent washing of the abscess. An ephemeral aggravation of infectious signs was observed just after creation of an artificial anus, and CZOP was again administered, and no evident bacterial infection occurred. The patient recovered, then was followed as an outpatient to date. A CAZ-resistant (MIC, > 16 micrograms/ml) E. coli was recovered from pus of her wound abscess. Since the CAZ-resistance decreased (MIC, 64 micrograms/ml-->0.13 microgram/ml) by the presence of clavulanate (CVA) in this isolate, this strain was speculated to be an extended spectrum beta-lactamase (ESBL) producer at an early stage of infection. A similar strain was also isolated from the feces. Therefore, we immediately took measures to block the nosocomial spread of this microorganism, and we succeeded in preventing a nosocomial outbreak of this strain. It was later confirmed by PCR analysis and DNA sequencing analysis that this CAZ-resistant E. coli strain produces an ESBL (SHV-5-2a = SHV-12). This is the first report of a case of infection with SHV-derived ESBL producing E. coli strain in Japan. We are concerned that further dissemination of this kind of microorganism might occur in the near future also in Japan, as it has been widely observed in European countries and the US. We believe that it will be very important to distinguish the type of beta-lactamases for rigorous bacterial infection control with the prudent use of antibiotics. In other words, we in Japan must recall that various gram-negative bacterial species that produce TEM-, SHV-derived ESBLs, Toho-1, AmpC, or IMP-1 are already widespread. Thus, we should take this fact into consideration when we do antibiotic susceptibility tentings and interpretation of the results for promotion of accurate chemotherapy.
Nakamura
T
T
Department of Clinical Central Laboratory, Kansai Medical University Hospital.
Uchida
S
S
Heijyo
H
H
Masuda
M
M
Takahashi
H
H
Komatsu
M
M
Aihara
M
M
Kurokawa
H
H
Shibata
N
N
Yagi
T
T
Arakawa
Y
Y
D000038:Abscess / Q000382:microbiology*; D002277:Carcinoma / Q000601:surgery*; D004926:Escherichia coli / Q000201:enzymology* / Q000302:isolation & purification*; D005260:Female; D006801:Humans; D008875:Middle Aged; D012004:Rectal Neoplasms / Q000601:surgery*; D013492:Suppuration / Q000382:microbiology; D013530:Surgical Wound Infection / Q000382:microbiology*; D018440:beta-Lactam Resistance; D001618:beta-Lactamases / Q000378:metabolism*
C107198:beta-lactamase SHV-12; D001618:beta-Lactamases